🔗 Share this article

The first new treatments for gonorrhoea in a generation are being viewed as a "significant breakthrough" in the fight against superbug strains of the infection, according to scientists.

A Worldwide Public Health Issue

Cases of gonorrhoea are on the rise worldwide, with data suggesting in excess of 82 million infections per year. Notably increased rates are observed in Africa and countries within the WHO's Western Pacific region, which spans from China and Mongolia to New Zealand. In England, cases have hit a all-time high, while infection numbers across Europe in 2023 were triple the level compared to those in 2014.

“The authorization of novel therapies for gonorrhoea is an significant and necessary development in the face of growing infection rates, escalating drug resistance and the extremely scarce therapeutic options currently available.”

Medical experts are particularly alarmed about the increase in drug-resistant strains. The WHO has designated it as a "priority pathogen". Recent surveillance showed that resistance to key first-line drugs like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Two New Treatment Options Secure Clearance

One new antibiotic, marketed under the name a brand name, was authorized by the US Food and Drug Administration in recent days for treating gonorrhoea. This STI can lead to serious health problems, including infertility. Experts hope that specific application of this new drug will help slow the development of resistance.

Another new antibiotic, developed by the drugmaker GSK, gained clearance in close succession. This medication, which is also used to treat urinary tract infections, was shown in trials to be effective against superbug versions of the gonorrhoea bacteria.

A Unique Partnership

This new treatment emerged from a unique collaborative effort for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the drug firm its industry partner to bring it to fruition.

“This approval represents a huge turning point in the treatment of multidrug-resistant gonorrhoea, which up to this point has been outpacing antibiotic development.”

Research Study Results and Global Access

According to findings published in a major medical journal, the new drug eradicated the vast majority of cases of the STI. This places it at an similar efficacy with the current standard treatment, which combines a dual-drug approach. The research enrolled hundreds of participants from multiple nations including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its collaboration, GARDP has the authority to license and sell the drug in numerous low-income and middle-income countries.

Medical professionals on the front lines have voiced optimism. Access to a easy-to-administer therapy of this kind is seen as a "critical tool" for public health efforts. This is viewed as essential to reduce the burden of the disease for patients and to halt the transmission of extremely resistant gonorrhoea around the world.